中国医药：子公司富马酸伏诺拉生片获得药品注册证书

Core Viewpoint - The announcement highlights the approval of two drug registration certificates for Fumaric Acid Vonoprazan Tablets by Tianfang Pharmaceutical, a wholly-owned subsidiary of China Pharmaceutical, indicating a significant development in the company's product portfolio and market presence in the treatment of gastroesophageal reflux disease and Helicobacter pylori eradication [1] Group 1 - The drug is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The drug was developed by Takeda Pharmaceutical and was launched in Japan in December 2014, followed by its introduction to the Chinese market in December 2019 [1] - As of the announcement date, a total of 39 domestic manufacturers, including Tiandi Hengyi Pharmaceutical Co., Ltd. and Guangdong Dongyangguang Pharmaceutical Co., Ltd., have obtained production licenses for this drug [1]